AbbVie Inc. 41st Annual J.P. Morgan HC meetg Rick Gonzalez - Chairman and Chief Executive Officer
Moving to Slide 13. We're the clear leader in aesthetics, a $14 billion global market, which is largely cash pay. Our portfolio is anchored by well-known brands that span several core areas, including Botox Cosmetic, the market leading neurotoxin, JUVEDERM, a leading portfolio of injectable and dermal fillers, as well as numerous products and technologies for body contouring, plastics, skincare, and regenerative medicine.
We see substantial room for further market penetration across each of the aesthetic categories and we've made strategic investments to support that long-term growth. Those efforts include a focus on new product innovation, including a pipeline of innovative toxins, as well as novel biostimulatory and regenerative fillers. Targeted field force expansion in major global markets including China, Japan, and Latin America, as well as increased direct-to-consumer and enhanced services to drive consumer activation and retention.
As a predominantly consumer facing category, aesthetic treatment procedures can be impacted by changing economic conditions. And while it's difficult to predict, how inflation and consumer confidence may play out this year in the U.S., our large installed base of existing patients, as well as the rapid and sustained recovery of our aesthetics portfolio experienced following the 2008, 2009 recession gives us a tremendous amount of confidence that any near-term economic impact will be transient.
Over the long-term, aesthetics continues to be an extremely attractive underpenetrated market with significant growth potential. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029.
AbbVie Inc. (ABBV) 41st Annual J.P. Morgan Healthcare Conference - (Transcript) | Seeking Alpha